The purpose of this study is to evaluate the safety and efficacy of ATN-103 when administered to subjects with active rheumatoid arthritis compared with placebo. All subjects must be on a stable dose and route of methotrexate.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
252
American College of Rheumatology (ACR) 20 response at week 16
Time frame: 6 months
Additional efficacy endpoints as measured by the number of swollen and tender joints, physician and patient global assessments of disease activity, ACR responses, DAS28, EULAR, and Health Outcome Assessments
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
80 mg every 4 weeks until week 12
80 mg every 8 weeks until week 12
Placebo every 4 weeks
Investigational Site
Birmingham, Alabama, United States
Investigational Site
Huntsville, Alabama, United States
Investigational Site
Peoria, Arizona, United States
Investigational Site
Scottsdale, Arizona, United States
Investigational Site
Riverside, California, United States
Investigational Site
Upland, California, United States
Investigational Site
Bridgeport, Connecticut, United States
Investigational Site
Newark, Delaware, United States
Investigational Site
Lake Mary, Florida, United States
Investigational Site
Ocala, Florida, United States
...and 57 more locations